Literature DB >> 26609178

Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times.

Milan Grkovski1, Jazmin Schwartz2, Mithat Gönen3, Heiko Schöder4, Nancy Y Lee5, Sean D Carlin4, Pat B Zanzonico2, John L Humm2, Sadek A Nehmeh2.   

Abstract

UNLABELLED: (18)F-fluoromisonidazole dynamic PET (dPET) is used to identify tumor hypoxia noninvasively. Its routine clinical implementation, however, has been hampered by the long acquisition times required. We investigated the feasibility of kinetic modeling using shortened acquisition times in (18)F-fluoromisonidazole dPET, with the goal of expediting the clinical implementation of (18)F-fluoromisonidazole dPET protocols.
METHODS: Six patients with squamous cell carcinoma of the head and neck and 10 HT29 colorectal carcinoma-bearing nude rats were studied. In addition to an (18)F-FDG PET scan, each patient underwent a 45-min (18)F-fluoromisonidazole dPET scan, followed by 10-min acquisitions at 96 ± 4 and 163 ± 17 min after injection. Ninety-minute (18)F-fluoromisonidazole dPET scans were acquired in animals. Intratumor voxels were classified into 4 clusters based on their kinetic behavior using k-means clustering. Kinetic modeling was performed using the foregoing full datasets (FD) and repeated for each of 2 shortened datasets corresponding to the first approximately 100 min (SD1; patients only) or the first 45 min (SD2) of dPET data. The kinetic rate constants (KRCs) as calculated with a 2-compartment model for both SD1 and SD2 were compared with those derived from FD by correlation (Pearson), regression (Passing-Bablok), deviation (Bland-Altman), and classification (area-under-the-receiver-operating characteristic curve) analyses. Simulations were performed to assess uncertainties due to statistical noise.
RESULTS: Strong correlation (r ≥ 0.75, P < 0.001) existed between all KRCs deduced from both SD1 and SD2, and from FD. Significant differences between KRCs were found only for FD-SD2 correlations in patient studies. K1 and k3 were reproducible to within approximately 6% and approximately 30% (FD-SD1; patients) and approximately 4% and approximately 75% (FD-SD2; animals). Area-under-the-receiver-operating characteristic curve values for classification of patient clusters as hypoxic, using a tumor-to-blood ratio greater than 1.2, were 0.91 (SD1) and 0.86 (SD2). The percentage SD in estimating K1 and k3 from 45-min shortened datasets due to noise was less than 1% and between 2% and 12%, respectively.
CONCLUSION: Using single-session 45-min shortened (18)F-fluoromisonidazole dPET datasets appears to be adequate for the identification of intratumor regions of hypoxia. However, k3 was significantly overestimated in the clinical cohort. Further studies are necessary to evaluate the clinical significance of differences between the results as calculated from full and shortened datasets.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  18F-fluoromisonidazole; dynamic PET; hypoxia; kinetic modeling

Mesh:

Substances:

Year:  2015        PMID: 26609178      PMCID: PMC4977990          DOI: 10.2967/jnumed.115.160168

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  26 in total

1.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole.

Authors:  W J Koh; J S Rasey; M L Evans; J R Grierson; T K Lewellen; M M Graham; K A Krohn; T W Griffin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

3.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck.

Authors:  M Nordsmark; M Overgaard; J Overgaard
Journal:  Radiother Oncol       Date:  1996-10       Impact factor: 6.280

4.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients.

Authors:  J S Rasey; W J Koh; M L Evans; L M Peterson; T K Lewellen; M M Graham; K A Krohn
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-09-01       Impact factor: 7.038

5.  Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET.

Authors:  Morten Busk; Ole Lajord Munk; Steen Jakobsen; Tobias Wang; Marianne Skals; Torben Steiniche; Michael Robert Horsman; Jens Overgaard
Journal:  Acta Oncol       Date:  2010-10       Impact factor: 4.089

6.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.

Authors:  Susanne-Martina Eschmann; Frank Paulsen; Matthias Reimold; Helmut Dittmann; Stefan Welz; Gerald Reischl; Hans-Juergen Machulla; Roland Bares
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

7.  Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer.

Authors:  Wenli Wang; Nancy Y Lee; Jens-Christoph Georgi; Manoj Narayanan; Jose Guillem; Heiko Schöder; John L Humm
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

8.  An efficient radiosynthesis of [18F]fluoromisonidazole.

Authors:  J L Lim; M S Berridge
Journal:  Appl Radiat Isot       Date:  1993-08       Impact factor: 1.513

9.  The influence of tissue heterogeneity on results of fitting nonlinear model equations to regional tracer uptake curves: with an application to compartmental models used in positron emission tomography.

Authors:  K Herholz; C S Patlak
Journal:  J Cereb Blood Flow Metab       Date:  1987-04       Impact factor: 6.200

10.  Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer.

Authors:  Daniela Thorwarth; Susanne-Martina Eschmann; Jutta Scheiderbauer; Frank Paulsen; Markus Alber
Journal:  BMC Cancer       Date:  2005-12-01       Impact factor: 4.430

View more
  9 in total

1.  Imaging Hypoxia with ¹⁸F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis.

Authors:  Mark Muzi; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2016-02-18       Impact factor: 10.057

2.  18F-Fluoromisonidazole Kinetic Modeling for Characterization of Tumor Perfusion and Hypoxia in Response to Antiangiogenic Therapy.

Authors:  Milan Grkovski; Sally-Ann Emmas; Sean D Carlin
Journal:  J Nucl Med       Date:  2017-03-30       Impact factor: 10.057

3.  Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic 18F-FMISO PET for Head and Neck Cancer Radiotherapy.

Authors:  Daniela Thorwarth; Stefan Welz; David Mönnich; Christina Pfannenberg; Konstantin Nikolaou; Matthias Reimold; Christian La Fougère; Gerald Reischl; Paul-Stefan Mauz; Frank Paulsen; Markus Alber; Claus Belka; Daniel Zips
Journal:  J Nucl Med       Date:  2019-05-10       Impact factor: 10.057

Review 4.  Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy.

Authors:  Sonja Stieb; Afroditi Eleftheriou; Geoffrey Warnock; Matthias Guckenberger; Oliver Riesterer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-20       Impact factor: 9.236

5.  Pharmacokinetic Analysis of Dynamic 18F-Fluoromisonidazole PET Data in Non-Small Cell Lung Cancer.

Authors:  Jazmin Schwartz; Milan Grkovski; Andreas Rimner; Heiko Schöder; Pat B Zanzonico; Sean D Carlin; Kevin D Staton; John L Humm; Sadek A Nehmeh
Journal:  J Nucl Med       Date:  2017-02-23       Impact factor: 10.057

6.  Inter-operator variability in compartmental kinetic analysis of 18F-fluoromisonidazole dynamic PET.

Authors:  Sadek A Nehmeh; Jazmin Schwartz; Milan Grkovski; Ivan Yeung; Charles M Laymon; Mark Muzi; John L Humm
Journal:  Clin Imaging       Date:  2018-01-12       Impact factor: 1.605

7.  18F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases.

Authors:  Milan Grkovski; Zachary A Kohutek; Heiko Schöder; Cameron W Brennan; Viviane S Tabar; Philip H Gutin; Zhigang Zhang; Robert J Young; Bradley J Beattie; Pat B Zanzonico; Jason T Huse; Marc K Rosenblum; Ronald G Blasberg; John L Humm; Kathryn Beal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-21       Impact factor: 9.236

8.  Multiparametric Imaging of Tumor Hypoxia and Perfusion with 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer.

Authors:  Milan Grkovski; Heiko Schöder; Nancy Y Lee; Sean D Carlin; Bradley J Beattie; Nadeem Riaz; Jonathan E Leeman; Joseph A O'Donoghue; John L Humm
Journal:  J Nucl Med       Date:  2017-02-09       Impact factor: 10.057

9.  Pharmacokinetic Assessment of 18F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer.

Authors:  Milan Grkovski; Reema Goel; Simone Krebs; Kevin D Staton; James J Harding; Ingo K Mellinghoff; John L Humm; Mark P S Dunphy
Journal:  J Nucl Med       Date:  2019-10-10       Impact factor: 11.082

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.